Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

NCT05221320 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

47

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of Enrollment for Remaining Open Baskets

Conditions

Tumor, Solid
Gastrointestinal Cancer

Interventions

DRUG: Ulixertinib
DRUG: Hydroxychloroquine

Sponsor

BioMed Valley Discoveries, Inc